Genetic risk for schizophrenia and psychosis in Alzheimer disease

M. A.A. Demichele-Sweet, E. A. Weamer, L. Klei, D. T. Vrana, D. J. Hollingshead, H. J. Seltman, R. Sims, Tatiana Foroud, I. Hernandez, S. Moreno-Grau, L. Tárraga, M. Boada, A. Ruiz, J. Williams, R. Mayeux, O. L. Lopez, E. L. Sibille, M. I. Kamboh, B. Devlin, R. A. Sweet

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD), affecting ∼40 to 60% of individuals with AD (AD with psychosis (AD+P)). In comparison with AD subjects without psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes. Prior studies have estimated the heritability of psychosis in AD at 61%, but the underlying genetic sources of this risk are not known. We evaluated a Discovery Cohort of 2876 AD subjects with (N=1761) or without psychosis (N=1115). All subjects were genotyped using a custom genotyping array designed to evaluate single-nucleotide polymorphisms (SNPs) with evidence of genetic association with AD+P and include SNPs affecting or putatively affecting risk for schizophrenia and AD. Results were replicated in an independent cohort of 2194 AD subjects with (N=734) or without psychosis (N=1460). We found that AD+P is associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for schizophrenia. Among the biologic pathways identified by the associations of schizophrenia SNPs with AD+P are endosomal trafficking, autophagy and calcium channel signaling. To the best of our knowledge, these findings provide the first clear demonstration that AD+P is associated with common genetic variation. In addition, they provide an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. This provides an opportunity to leverage progress made in identifying the biologic effects of schizophrenia alleles to identify novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.

Original languageEnglish (US)
Pages (from-to)963-972
Number of pages10
JournalMolecular Psychiatry
Volume23
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Psychotic Disorders
Schizophrenia
Alzheimer Disease
Single Nucleotide Polymorphism
Delusions
Calcium Signaling
Hallucinations
Autophagy
Calcium Channels

ASJC Scopus subject areas

  • Molecular Biology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this

Demichele-Sweet, M. A. A., Weamer, E. A., Klei, L., Vrana, D. T., Hollingshead, D. J., Seltman, H. J., ... Sweet, R. A. (2018). Genetic risk for schizophrenia and psychosis in Alzheimer disease. Molecular Psychiatry, 23(4), 963-972. https://doi.org/10.1038/mp.2017.81

Genetic risk for schizophrenia and psychosis in Alzheimer disease. / Demichele-Sweet, M. A.A.; Weamer, E. A.; Klei, L.; Vrana, D. T.; Hollingshead, D. J.; Seltman, H. J.; Sims, R.; Foroud, Tatiana; Hernandez, I.; Moreno-Grau, S.; Tárraga, L.; Boada, M.; Ruiz, A.; Williams, J.; Mayeux, R.; Lopez, O. L.; Sibille, E. L.; Kamboh, M. I.; Devlin, B.; Sweet, R. A.

In: Molecular Psychiatry, Vol. 23, No. 4, 01.04.2018, p. 963-972.

Research output: Contribution to journalArticle

Demichele-Sweet, MAA, Weamer, EA, Klei, L, Vrana, DT, Hollingshead, DJ, Seltman, HJ, Sims, R, Foroud, T, Hernandez, I, Moreno-Grau, S, Tárraga, L, Boada, M, Ruiz, A, Williams, J, Mayeux, R, Lopez, OL, Sibille, EL, Kamboh, MI, Devlin, B & Sweet, RA 2018, 'Genetic risk for schizophrenia and psychosis in Alzheimer disease', Molecular Psychiatry, vol. 23, no. 4, pp. 963-972. https://doi.org/10.1038/mp.2017.81
Demichele-Sweet MAA, Weamer EA, Klei L, Vrana DT, Hollingshead DJ, Seltman HJ et al. Genetic risk for schizophrenia and psychosis in Alzheimer disease. Molecular Psychiatry. 2018 Apr 1;23(4):963-972. https://doi.org/10.1038/mp.2017.81
Demichele-Sweet, M. A.A. ; Weamer, E. A. ; Klei, L. ; Vrana, D. T. ; Hollingshead, D. J. ; Seltman, H. J. ; Sims, R. ; Foroud, Tatiana ; Hernandez, I. ; Moreno-Grau, S. ; Tárraga, L. ; Boada, M. ; Ruiz, A. ; Williams, J. ; Mayeux, R. ; Lopez, O. L. ; Sibille, E. L. ; Kamboh, M. I. ; Devlin, B. ; Sweet, R. A. / Genetic risk for schizophrenia and psychosis in Alzheimer disease. In: Molecular Psychiatry. 2018 ; Vol. 23, No. 4. pp. 963-972.
@article{f8031a12b37842caafa140f14f6f5266,
title = "Genetic risk for schizophrenia and psychosis in Alzheimer disease",
abstract = "Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD), affecting ∼40 to 60{\%} of individuals with AD (AD with psychosis (AD+P)). In comparison with AD subjects without psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes. Prior studies have estimated the heritability of psychosis in AD at 61{\%}, but the underlying genetic sources of this risk are not known. We evaluated a Discovery Cohort of 2876 AD subjects with (N=1761) or without psychosis (N=1115). All subjects were genotyped using a custom genotyping array designed to evaluate single-nucleotide polymorphisms (SNPs) with evidence of genetic association with AD+P and include SNPs affecting or putatively affecting risk for schizophrenia and AD. Results were replicated in an independent cohort of 2194 AD subjects with (N=734) or without psychosis (N=1460). We found that AD+P is associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for schizophrenia. Among the biologic pathways identified by the associations of schizophrenia SNPs with AD+P are endosomal trafficking, autophagy and calcium channel signaling. To the best of our knowledge, these findings provide the first clear demonstration that AD+P is associated with common genetic variation. In addition, they provide an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. This provides an opportunity to leverage progress made in identifying the biologic effects of schizophrenia alleles to identify novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.",
author = "Demichele-Sweet, {M. A.A.} and Weamer, {E. A.} and L. Klei and Vrana, {D. T.} and Hollingshead, {D. J.} and Seltman, {H. J.} and R. Sims and Tatiana Foroud and I. Hernandez and S. Moreno-Grau and L. T{\'a}rraga and M. Boada and A. Ruiz and J. Williams and R. Mayeux and Lopez, {O. L.} and Sibille, {E. L.} and Kamboh, {M. I.} and B. Devlin and Sweet, {R. A.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1038/mp.2017.81",
language = "English (US)",
volume = "23",
pages = "963--972",
journal = "Molecular Psychiatry",
issn = "1359-4184",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Genetic risk for schizophrenia and psychosis in Alzheimer disease

AU - Demichele-Sweet, M. A.A.

AU - Weamer, E. A.

AU - Klei, L.

AU - Vrana, D. T.

AU - Hollingshead, D. J.

AU - Seltman, H. J.

AU - Sims, R.

AU - Foroud, Tatiana

AU - Hernandez, I.

AU - Moreno-Grau, S.

AU - Tárraga, L.

AU - Boada, M.

AU - Ruiz, A.

AU - Williams, J.

AU - Mayeux, R.

AU - Lopez, O. L.

AU - Sibille, E. L.

AU - Kamboh, M. I.

AU - Devlin, B.

AU - Sweet, R. A.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD), affecting ∼40 to 60% of individuals with AD (AD with psychosis (AD+P)). In comparison with AD subjects without psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes. Prior studies have estimated the heritability of psychosis in AD at 61%, but the underlying genetic sources of this risk are not known. We evaluated a Discovery Cohort of 2876 AD subjects with (N=1761) or without psychosis (N=1115). All subjects were genotyped using a custom genotyping array designed to evaluate single-nucleotide polymorphisms (SNPs) with evidence of genetic association with AD+P and include SNPs affecting or putatively affecting risk for schizophrenia and AD. Results were replicated in an independent cohort of 2194 AD subjects with (N=734) or without psychosis (N=1460). We found that AD+P is associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for schizophrenia. Among the biologic pathways identified by the associations of schizophrenia SNPs with AD+P are endosomal trafficking, autophagy and calcium channel signaling. To the best of our knowledge, these findings provide the first clear demonstration that AD+P is associated with common genetic variation. In addition, they provide an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. This provides an opportunity to leverage progress made in identifying the biologic effects of schizophrenia alleles to identify novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.

AB - Psychotic symptoms, defined as the occurrence of delusions or hallucinations, are frequent in Alzheimer disease (AD), affecting ∼40 to 60% of individuals with AD (AD with psychosis (AD+P)). In comparison with AD subjects without psychosis, AD+P subjects have more rapid cognitive decline and poor outcomes. Prior studies have estimated the heritability of psychosis in AD at 61%, but the underlying genetic sources of this risk are not known. We evaluated a Discovery Cohort of 2876 AD subjects with (N=1761) or without psychosis (N=1115). All subjects were genotyped using a custom genotyping array designed to evaluate single-nucleotide polymorphisms (SNPs) with evidence of genetic association with AD+P and include SNPs affecting or putatively affecting risk for schizophrenia and AD. Results were replicated in an independent cohort of 2194 AD subjects with (N=734) or without psychosis (N=1460). We found that AD+P is associated with polygenic risk for a set of novel loci and inversely associated with polygenic risk for schizophrenia. Among the biologic pathways identified by the associations of schizophrenia SNPs with AD+P are endosomal trafficking, autophagy and calcium channel signaling. To the best of our knowledge, these findings provide the first clear demonstration that AD+P is associated with common genetic variation. In addition, they provide an unbiased link between polygenic risk for schizophrenia and a lower risk of psychosis in AD. This provides an opportunity to leverage progress made in identifying the biologic effects of schizophrenia alleles to identify novel mechanisms protecting against more rapid cognitive decline and psychosis risk in AD.

UR - http://www.scopus.com/inward/record.url?scp=85044251696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044251696&partnerID=8YFLogxK

U2 - 10.1038/mp.2017.81

DO - 10.1038/mp.2017.81

M3 - Article

C2 - 28461698

AN - SCOPUS:85044251696

VL - 23

SP - 963

EP - 972

JO - Molecular Psychiatry

JF - Molecular Psychiatry

SN - 1359-4184

IS - 4

ER -